Document Detail

Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
MedLine Citation:
PMID:  16755277     Owner:  NLM     Status:  MEDLINE    
Lipoprotein lipase (LPL) hydrolyzes circulating triglycerides (TGs). We previously showed that 3'-end haplotypes in the LPL gene influence atherosclerosis and insulin resistance. This study asked whether these LPL haplotypes influence response to lipid-lowering therapy among 829 subjects from the Post-Coronary Artery Bypass Graft trial. Lipid profiles were obtained at baseline and 4-5 years after treatment with lovastatin. Haplotypes were based on 12 SNPs. The fourth most frequent haplotype, 12-4, was associated with a decreased increment in high-density lipoprotein-cholesterol (HDL-C) following treatment. Haplotypes 12-6, 12-7 and 12-8 were each associated with increased HDL-C response to therapy, and haplotype 12-2 with decreased TG response. The most common haplotype, 12-1, was protective against graft worsening or occlusion. Haplotype 12-4 reduced HDL-C response to lovastatin, possibly consistent with our prior observations of this haplotype as predisposing to coronary artery disease. LPL may influence atherosclerosis risk through pleiotropic effects on each aspect of the metabolic syndrome.
M O Goodarzi; K D Taylor; M T Scheuner; H J Antoine; X Guo; P K Shah; J I Rotter
Related Documents :
9359537 - Rationale, design, and baseline characteristics of a trial comparing aggressive lipid l...
9117137 - Lipid-lowering trials in the primary and secondary prevention of coronary heart disease...
9386157 - Association between serum amyloid a proteins and coronary artery disease: evidence from...
9148647 - Clarifying the direct relation between total cholesterol levels and death from coronary...
19725857 - Baseline echocardiographic predictors of dynamic intraventricular obstruction of the le...
8857237 - Lipoprotein(a) in cerebrovascular and coronary atherosclerosis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-06-06
Journal Detail:
Title:  The pharmacogenomics journal     Volume:  7     ISSN:  1470-269X     ISO Abbreviation:  Pharmacogenomics J.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-22     Completed Date:  2007-06-20     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  101083949     Medline TA:  Pharmacogenomics J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  66-73     Citation Subset:  IM    
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA 9048, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use*
Atherosclerosis / drug therapy*,  genetics*,  pathology
Blood Pressure / physiology
Cholesterol, HDL / genetics*
Cohort Studies
Coronary Artery Bypass*
Coronary Restenosis / drug therapy*,  genetics*,  pathology
Disease Progression
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Insulin Resistance / genetics
Lipoprotein Lipase / genetics*
Mexican Americans
Middle Aged
Polymorphism, Single Nucleotide
Reverse Transcriptase Polymerase Chain Reaction
Grant Support
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; EC Lipase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia.
Next Document:  Repair of spinal cord injury: ripples of an incoming tide, or how I spent my first 40 years in resea...